tiprankstipranks
BerGenBio AS (BRRGF)
OTHER OTC:BRRGF

BerGenBio AS (BRRGF) Stock Price & Analysis

37 Followers

BRRGF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.03 - $0.14
Previous Close$0.03
Volume37.30K
Average Volume (3M)N/A
Market Cap
$48.31M
Enterprise Value$456.14M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$407.83M
Price to Earnings (P/E)-0.7
Beta0.44
May 29, 2024
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,688,689,214
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.60
R-Squared0.00094
Alpha-0.00157
Financial Highlights & Ratios
Price to Book (P/B)2.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.74
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.37
Forecast
Price Target Upside660.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%<0.01%<0.01%100.00%
0.00%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

BRRGF FAQ

What was BerGenBio AS’s price range in the past 12 months?
BerGenBio AS lowest stock price was $0.03 and its highest was $0.14 in the past 12 months.
    What is BerGenBio AS’s market cap?
    Currently, no data Available
    When is BerGenBio AS’s upcoming earnings report date?
    BerGenBio AS’s upcoming earnings report date is May 29, 2024 which is in 61 days.
      How were BerGenBio AS’s earnings last quarter?
      BerGenBio AS released its earnings results on Feb 14, 2024. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of >-$0.001 by >-$0.001.
        Is BerGenBio AS overvalued?
        According to Wall Street analysts BerGenBio AS’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does BerGenBio AS pay dividends?
          BerGenBio AS does not currently pay dividends.
          What is BerGenBio AS’s EPS estimate?
          BerGenBio AS’s EPS estimate is >-$0.01.
            How many shares outstanding does BerGenBio AS have?
            BerGenBio AS has 2,688,689,200 shares outstanding.
              What happened to BerGenBio AS’s price movement after its last earnings report?
              BerGenBio AS reported an EPS of -$0.002 in its last earnings report, missing expectations of >-$0.001. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of BerGenBio AS?
                Currently, no hedge funds are holding shares in BRRGF
                ---

                BerGenBio AS Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                BerGenBio AS

                BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
                ---

                BRRGF Stock 12 Months Forecast

                Average Price Target

                $0.19
                ▲(660.00% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.18594094,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$0.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$0.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.18594094,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$0.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.03276468769230769,0.045529375384615385,0.05829406307692307,0.07105875076923077,0.08382343846153846,0.09658812615384615,0.10935281384615385,0.12211750153846154,0.13488218923076922,0.1476468769230769,0.1604115646153846,0.1731762523076923,{"y":0.18594094,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.03307692307692308,0.046153846153846156,0.05923076923076924,0.07230769230769231,0.08538461538461539,0.09846153846153848,0.11153846153846154,0.12461538461538463,0.1376923076923077,0.15076923076923077,0.16384615384615384,0.17692307692307693,{"y":0.19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.03276468769230769,0.045529375384615385,0.05829406307692307,0.07105875076923077,0.08382343846153846,0.09658812615384615,0.10935281384615385,0.12211750153846154,0.13488218923076922,0.1476468769230769,0.1604115646153846,0.1731762523076923,{"y":0.18594094,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.08,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.08,"date":1682640000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1683244800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Bioxcel Therapeutics
                Crispr Therapeutics AG
                Kura Oncology
                MacroGenics

                Best Analysts Covering BRRGF

                1 Year
                Joseph PantginisH.C. Wainwright
                1 Year Success Rate
                1/9 ratings generated profit
                11%
                1 Year Average Return
                -38.07%
                reiterated a buy rating 8 days ago
                Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -38.07% per trade.
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis